Literature DB >> 8705685

Time to peak serum antibody response to influenza vaccine in the elderly.

P A Gross1, C Russo, M Teplitzky, S Dran, P Cataruozolo, G Munk.   

Abstract

The earliest time at which serum antibody peaks following administration of influenza virus vaccine in elderly persons is not clearly defined. We compared the time intervals of 2 and 4 weeks after vaccination. A commercial trivalent vaccine containing the hemagglutinins of influenza viruses A/Texas/36/91(H1N1), A/Shangdong/9/93(H3N2), and B/Panama/45/90 was used. The hemagglutination inhibition antibody titers at 2 weeks after vaccination were identical to the hemagglutination inhibition antibody titers at 4 weeks for all three vaccine components.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8705685      PMCID： PMC170348          DOI： 10.1128/cdli.3.3.361-362.1996

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


  5 in total

1.  Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine.

Authors:  M L Clements; B R Murphy
Journal:  J Clin Microbiol       Date:  1986-01       Impact factor: 5.948

2.  A Hong Kong influenza immunity three years after immunization.

Authors:  H M Foy; M K Cooney; R McMahan
Journal:  JAMA       Date:  1973-11-12       Impact factor: 56.272

3.  Neutralization test in influenza: use in individuals without hemagglutination inhibition antibody.

Authors:  P A Gross; A E Davis
Journal:  J Clin Microbiol       Date:  1979-09       Impact factor: 5.948

4.  Time to peak serum antibody response to influenza vaccine.

Authors:  S Rastogi; P A Gross; J Bonelli; S Dran; R A Levandowski; C Russo; M E Weksler; D Kaye; M Levison; E Abrutyn
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

5.  A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children.

Authors:  P A Gross; F A Ennis; P F Gaerlan; L J Denson; C R Denning; D Schiffman
Journal:  J Infect Dis       Date:  1977-11       Impact factor: 5.226
  5 in total
  11 in total

1.  Time to earliest peak serum antibody response to influenza vaccine in the elderly.

Authors:  P A Gross; C Russo; S Dran; P Cataruozolo; G Munk; S C Lancey
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

2.  Comparison of complement fixation and hemagglutination inhibition assays for detecting antibody responses following influenza virus vaccination.

Authors:  Harry E Prince; Amy L Leber
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

3.  Perspective on potential clinical applications of recombinant human interleukin-7.

Authors:  Claude Sportès; Ronald E Gress; Crystal L Mackall
Journal:  Ann N Y Acad Sci       Date:  2009-12       Impact factor: 5.691

4.  Comparison of immunogenicity between intradermal and intramuscular injections of repeated annual identical influenza virus strains post-pandemic (2011-2012) in COPD patients.

Authors:  Benjamas Chuaychoo; Uraiwan Kositanont; Parichat Niyomthong; Nuttapol Rittayamai; Sorachai Srisuma; Kanokwan Rattanasaengloet; Walaiporn Wongsrisakunkaew; Julalux Thongam; Thaweesak Songserm
Journal:  Hum Vaccin Immunother       Date:  2019-11-26       Impact factor: 3.452

Review 5.  Humoral immune response to influenza vaccination in patients from high risk groups.

Authors:  L B Brydak; M Machala
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

6.  Persistence of influenza vaccine-induced antibody in lung transplant patients and healthy individuals beyond the season.

Authors:  Jill J Severson; Katelyn R Richards; John J M Moran; Mary S Hayney
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

7.  Decreased immune responses to influenza vaccination in patients with heart failure.

Authors:  Orly Vardeny; Nancy K Sweitzer; Michelle A Detry; John M Moran; Maryl R Johnson; Mary S Hayney
Journal:  J Card Fail       Date:  2008-12-18       Impact factor: 5.712

8.  Decreased T-cell responses to influenza vaccination in patients with heart failure.

Authors:  Orly Vardeny; John J M Moran; Nancy K Sweitzer; Maryl R Johnson; Mary S Hayney
Journal:  Pharmacotherapy       Date:  2010-01       Impact factor: 4.705

9.  Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination.

Authors:  Silvia Jiménez-Jorge; Salvador de Mateo; Concha Delgado-Sanz; Francisco Pozo; Inmaculada Casas; Manuel Garcia-Cenoz; Jesús Castilla; Esteban Pérez; Virtudes Gallardo; Carolina Rodriguez; Tomás Vega; Carmen Quiñones; Eva Martínez; Juana María Vanrell; Jaume Giménez; Daniel Castrillejo; María del Carmen Serrano; Julián Mauro Ramos; Amparo Larrauri
Journal:  BMC Infect Dis       Date:  2013-09-22       Impact factor: 3.090

10.  Effect of annual influenza immunization on antibody response in lung transplant patients.

Authors:  John M Dopp; Nicholas A Wiegert; John J M Moran; Mary L Francois; Kelly L Radford; Holly Thomas; Robert B Love; Mary S Hayney
Journal:  Prog Transplant       Date:  2009-06       Impact factor: 1.065
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.